NDA 215212 · Hq Spclt Pharma
Meropenem
Meropenem · Intravenous
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jul 26, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
186
58 Phase 3, 27 recruiting
FAERS reports
32,715
31,766 serious, 9,722 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
Meropenem for Injection is a penem antibacterial indicated for the treatment of bacterial meningitis in pediatric patients 3 months of age and older only. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae , Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae, in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Meropenem is an antibacterial drug [ see Microbiology ( 12.4 ) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MEROPENEM · MEROPENEM 2GM/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Meropenem" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)Pivotal-lookingRecruiting
Rambam Health Care CampusAcademic, hospital or other
NCT03671967 · 1,084 participants (planned) · Start May 1, 2019 · Primary completion Jan 1, 2027
Drug: Piperacillin/tazobactam; Meropenem · For: Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia
Sites: Calgary, Canada; Surrey, Canada; St. John's, Canada · 14 sites in all
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06080698 · 1,030 participants (planned) · Start Feb 22, 2024 · Primary completion May 31, 2027
Drug: Intravenous Antibiotics; Oral Antibiotics · For: Gram-negative Bacteremia
Sites: San Francisco, California; Denver, Colorado; Baltimore, Maryland · 11 sites in all
- Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingStatus unknown
WockhardtIndustry
NCT03630081 · 1,004 participants (planned) · Start Jan 2024 · Primary completion Jan 2026
Drug: WCK 4282 (FEP-TAZ) 4 g; Meropenem and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
- Complicated Skin and Skin Structure InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00619710 · 1,000 participants (planned) · Start Feb 2001 · Primary completion Dec 2003
Drug: Meropenem; Imipenem-cilastatin · For: Skin Infection; Abscess; Cellulitis
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial PneumoniaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01808092 · 969 participants · Start Apr 2013 · Primary completion Jan 2016
Drug: ceftazidim-avibactam (CAZ-AVI, experimental product); meropenem (active comparator) · For: Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Florida, Argentina · 123 sites in all
- The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)Pivotal-lookingRecruiting
Bassett HealthcareAcademic, hospital or other
NCT07556107 · 852 participants (planned) · Start Aug 17, 2026 · Primary completion Jun 30, 2028
Drug: Piperacillin + Tazobactam; meropenem · For: Infection; Acute Kidney Injury; Sepsis
Sites: Worcester, Massachusetts; Omaha, Nebraska; Cooperstown, New York · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,620
- off label use3,390
- pyrexia2,230
- pneumonia1,510
- septic shock1,472
- sepsis1,429
- multiple organ dysfunction syndrome1,356
- acute kidney injury1,317
- condition aggravated1,295
- thrombocytopenia1,153
- febrile neutropenia1,149
- respiratory failure1,143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 101 |
| 2005 | 99 |
| 2006 | 135 |
| 2007 | 203 |
| 2008 | 228 |
| 2009 | 299 |
| 2010 | 409 |
| 2011 | 737 |
| 2012 | 788 |
| 2013 | 666 |
| 2014 | 658 |
| 2015 | 870 |
| 2016 | 1,203 |
| 2017 | 1,529 |
| 2018 | 2,137 |
| 2019 | 2,342 |
| 2020 | 2,810 |
| 2021 | 3,235 |
| 2022 | 2,870 |
| 2023 | 2,878 |
| 2024 | 3,227 |
| 2025 | 3,082 |
| 2026 | 2,206 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Meropenem (Meropenem)
2024 spending
$17.5M
Beneficiaries
30,252
94,400 claims
Per beneficiary
$578
$4.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,597,180 |
| 2021 | $22,377,352 |
| 2022 | $20,251,807 |
| 2023 | $19,803,852 |
| 2024 | $17,498,300 |
Part B: Meropenem* (Meropenem*) · HCPCS J2185
2024 spending
$108K
Beneficiaries
997
12,122 claims
Per beneficiary
$108
2024 ASP limit $0.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $234,839 |
| 2021 | $239,571 |
| 2022 | $222,806 |
| 2023 | $161,358 |
| 2024 | $107,559 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, et al. · JAMA 2018 · Comparative Study, Equivalence Trial
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
Dulhunty JM, Brett SJ, De Waele JJ, et al. · JAMA 2024 · Comparative Study, Multicenter Study
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, et al. · Lancet Infect Dis 2025 · Clinical Trial, Phase III, Comparative Study
- Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Meropenem use and therapeutic drug monitoring in clinical practice: a literature review.
Steffens NA, Zimmermann ES, Nichelle SM, et al. · J Clin Pharm Ther 2021 · Systematic Review
- The risk of seizures among the carbapenems: a meta-analysis.
Cannon JP, Lee TA, Clark NM, et al. · J Antimicrob Chemother 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Hq Spclt Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.